Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
October 17, 2024 16:30 ET
|
Profound Medical Corp.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
October 16, 2024 16:15 ET
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA
September 16, 2024 08:00 ET
|
Profound Medical Corp.
- Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemens Healthineers and Cook...
Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference
September 04, 2024 16:30 ET
|
Profound Medical Corp.
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Second Quarter 2024 Financial Results
August 08, 2024 16:05 ET
|
Profound Medical Corp.
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
July 18, 2024 16:30 ET
|
Profound Medical Corp.
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
July 11, 2024 07:00 ET
|
Profound Medical Corp.
TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Annual General Meeting of Shareholders Voting Results
May 15, 2024 17:00 ET
|
Profound Medical Corp.
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
May 14, 2024 07:30 ET
|
Profound Medical Corp.
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – – Validated in standalone and multi-reader,...
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
May 09, 2024 16:05 ET
|
Profound Medical Corp.
TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...